news 2026

Experimental approach shows early promise; aim is more effective immunotherapy with fewer side effects Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have developed a new way to deliver cancer immunotherapy that caused fewer side effects compared to standard treatment in a preclinical study.

The nasally-administered vaccine currently under development could protect children aged 6 months to 5 years against bronchiolitis and pneumonia Human metapneumovirus and respiratory syncytial virus (RSV) cause numerous cases of bronchiolitis and pneumonia in children aged 6 months to 5 years every year.

Findings indicate vitamin B3 looks promising to help rearm a compromised immune system Edward (Ed) Waldner had no idea why he didn't feel well, but he knew he didn't feel like himself. At 55 years of age, he felt exhausted all the time. It didn't seem to matter how hard he had worked that day. He wondered if he had sleep apnea.

UCalgary's Healthy City Lab develops "route complexity metric" to track subtle changes in older adults' everyday navigation behind the wheel As drivers steering our way through each day, we make hundreds of tiny navigational decisions.

Study in human cells finds low-cost drug keeps virus dormant through an unexpected pathway, pointing the way to new treatments Lithium, a widely used treatment for bipolar disorder and other mood disorders, has shown early promise in suppressing HIV, McGill researchers report. A new study published in iScience found lithium can prevent infected cells from reactivating, and that it does so through an unexpected biological mechanism.

There is growing evidence that GLP-1 receptor agonists and DPP-4 inhibitors have protective benefits for the brain A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both incretin-based, are associated with a reduced risk of dementia. Drawing on clinical data from more than 450,000 patients, the research adds to growing evidence that incretin-based therapies have protective benefits for the brain.

Research team develops new drug to block antibodies involved in multiple sclerosis-like disease A study published today in the journal PNAS shows that it may be possible to slow the progression of certain autoimmune diseases using drugs that interfere with the antibodies responsible for these pathologies.